Objectives: Over the past two decades, there has been tremendous growth in research regarding bipolar disorder (BD) among children and adolescents (ie, pediatric BD
| INTRODUCTION
Over the past two decades, there has been tremendous growth in the scientific literature regarding bipolar disorder (BD) among children and adolescents (ie, pediatric BD [PBD]) ( Figure 1 ). The literature now contains numerous gold-standard clinical trials of pharmacologic agents for mania, an increasing evidence base for adjunctive psychosocial treatments, several large-scale prospective clinical cohort studies, representative epidemiologic studies (particularly focused on adolescents) with international representation, numerous neurocognitive and neuroimaging studies, and an accelerating number of biomarker studies. Despite the volume, quality, and international spectrum of available literature, and regardless of the general consensus about some of the field's previously most divisive and controversial topics, there remains a perspective in the popular press, other branches of medicine, and even within mental health that the field of PBD lacks evidence and is replete with controversy. Therefore, the primary purpose of this article is to distill the extant literature, dispel myths or exaggerated assertions in the field, and disseminate clinically relevant findings. In this paper, an international group of experts completed a selective review of the extant literature (including PubMed and Web of Science/ PsycINFO searches, querying other databases or conference proceedings and unpublished reports on an ad hoc basis), emphasizing areas of established findings and consensus, identifying limitations and gaps in the literature, and highlighting future directions to mitigate these gaps.
| EPIDEMIOLOGY

| Established findings and consensus
In community samples around the world, it is now well established that bipolar spectrum disorders-an umbrella that covers bipolar I disorder, bipolar II disorder, cyclothymic disorder [CycD], bipolar disorder not otherwise specified (NOS) and other specified bipolar and related disorders (OS-BRD)-occur in youths. The update of a published metaanalysis of epidemiologic studies 1 using an identical search strategy identified six new studies satisfying inclusion criteria. The update includes 17 studies (seven from the USA) with 31 443 youth aged Results: Substantial, and increasingly international, research has accumulated regarding the phenomenology, differential diagnosis, course, treatment, and neurobiology of PBD. Prior division around the role of irritability and of screening tools in diagnosis has largely abated. Gold-standard pharmacologic trials inform treatment of manic/mixed episodes, whereas fewer data address bipolar depression and maintenance/continuation treatment. Adjunctive psychosocial treatment provides a forum for psychoeducation and targets primarily depressive symptoms. Numerous neurocognitive and neuroimaging studies, and increasing peripheral biomarker studies, largely converge with prior findings from adults with BD.
Conclusions:
As data have accumulated and controversy has dissipated, the field has moved past existential questions about PBD toward defining and pursuing pressing clinical and scientific priorities that remain. The overall body of evidence supports the position that perceptions about marked international (US vs elsewhere) and developmental (pediatric vs adult) differences have been overstated, although additional research on these topics is warranted. Traction toward improved outcomes will be supported by continued emphasis on pathophysiology and novel therapeutics.
K E Y W O R D S
adolescent, bipolar disorder, child, pediatric, youth F I G U R E 1 Articles about pediatric bipolar disorder indexed in PubMed each year. Search terms were ("bipolar disorder" or mania or manic) and (child or adole* or pediatric or juvenile) [Colour figure can be viewed at wileyonlinelibrary.com] 7-21 years, 576 of whom met criteria for bipolar spectrum disorders. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] The updated weighted average prevalence rate of bipolar spectrum disorders is 2.06% (95% confidence interval [CI] 1.44%-2.95%).
There was substantial heterogeneity across studies, but it was not explained by year of data collection, lifetime prevalence (vs other time periods), or sex. Studies that included more adolescents had significantly higher prevalence estimates. Differences in the definition of BD explained the largest portion of variance between studies. As expected, broader definitions (ie, including NOS or CycD) had the highest rates while narrow definitions (ie, BD-I and -II only) had lower rates, but even this was not a complete explanation. The weighted average prevalence of BD-I was 0.49% (95% CI 0.22%-1.09%), with four of 12 studies reporting no BD-I cases. Although there is no epidemiologic study on PBD in Asia, several studies from clinical samples reported that PBD is also prevalent in Asia. [18] [19] [20] Community rates are not higher in the USA, nor do rates appear to be increasing over time. In contrast, billing and services data show a marked increase in rates of diagnoses in the USA over a 20-year period. 21, 22 Differences in training, conceptualization of cases and insurance demands appear more of a factor 23 than underlying differences in prevalence.
In summary, PBD prevalence rates appear relatively stable across studies. PBD is more common than autism or schizophrenia and much less common than depression or attention deficit hyperactivity disorder (ADHD) in the community; more data are available with post-pubertal samples, and they find higher rates than before puberty.
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| Limitations, gaps, and future directions
New epidemiologic studies need to systematically assess hypomania and mania and differentiate them from other non-mood psychopathology. Even the newest epidemiologic data were collected at least 10 years ago (range 1986-2005) , and fewer than 1% of indexed papers on pediatric epidemiology include data about BD. 1 Documenting age of onset of the first mood episode of each type will be vital, with more studies including prepubertal children, to clarify onset and course. If depression manifests first, it may not be clear that it is following a bipolar course until later. Onset age may be bimodal 25, 26 and American youth may be at higher risk for very early onset. 27 Existing literature confounds age and informant effects: studies with older participants are less likely to include interviews of parents. Studies relying only on retrospective self-report are likely to underestimate hypomania or mania, as people forget or minimize the events, whereas depression may be more salient. Using more consistent criteria across studies will reduce the largest source of variance identified in extant meta-analyses.
| INTERNATIONAL FINDINGS
| Established findings and consensus
Prior studies in adults suggested that, although BD occurs worldwide, there could be international differences in the clinical characteristics of BD, including age of onset, comorbidity, early adversity, and familiality. 28, 29 52 After controlling for age, rates of DSM-IV BD-I (2.2% in the US sample and 1.5% in the Dutch sample) and BD-II (2% and 1%, respectively) were similar. In contrast, other disorders were significantly more common in the US sample, including depressive disorders (13% vs 4% in the Dutch sample), anxiety disorders (31% vs 9%, respectively), ADHD (22% vs 8%, respectively), and disruptive behavior disorder (19% vs 6%, respectively). CBCL Externalizing scores were higher in the US sample (mean + standard deviation 15.0 + 9.7 vs 10.8 + 7.6, respectively, P = .03). However, Internalizing scores did not differ between samples (raw M ~ 15), despite higher rates of anxiety and depressive disorders in the US sample. In the US, fewer parents had BD-I, affected parents were younger at their own illness onset, parental substance abuse rates were higher, and rates of parental employment and youth living with both biological parents were lower. These stressors may have contributed to the greater rates of problems in the US sample. The differences also illustrate the importance of the psychopathology of the parent bipolar sample to understanding rates of offspring psychopathology. The internalizing findings also suggest that there could be differences in clinical interpretation of similar levels of pathology, even using semi-structured approaches.
| Limitations, gaps, and future directions
Future work needs to determine whether there are meaningful international differences in the prevalence, phenomenology, course, Ultra-rapid or "ultradian" cycling also has been associated with pediatric (as well as adult) BD. 67 Although youth with BD, particularly younger children, often have more mood fluctuations than adults, it appears that "ultra-rapid cycles" describes mood fluctuation within an episode, and they are not themselves distinct episodes.
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Similar to adult BD, PBD has extensive comorbidity, both in representative epidemiologic studies with largely untreated samples 17, 69, 70 and in clinical samples. 71 With the exception of developmental disorders like ADHD and autism spectrum disorders, the patterns of comorbidity are broadly consistent between youth and adult presentations. 71, 72 Apparent differences may partly reflect limited assessment of ADHD and autism spectrum disorders in adult samples rather than a true difference in comorbidities between these age groups, although some studies also suggest an association between ADHD and earlier age of onset of bipolar illness in adult samples. 73, 74 
| Differential diagnosis
Diagnosing PBD requires changes in mood and behavior that are un- The reliability of DMDD diagnoses was low in the DSM-5 field trials, suggesting that it may be challenging to accurately identify clinically.
| Course
Multiple longitudinal studies have prospectively followed cohorts of youths for 4 or more years. Consistent findings include (i) high rates of progression from BD-NOS or CycD to BD-I or BD-II (eg, 43%), 64 particularly in youth with a family history of BD; (ii) high rates of recovery from episodes, particularly with treatment (eg, 81.5%); 87, 88 (iii) high rates of recurrence of depression, hypomania, or mania (eg, 62.5%); 64, 87, 89, 90 and (iv) patterns of comorbidity 91 and treatment response congruent with adult BD. 92 The prodrome of BD-I or BD-II, often identified retrospectively in adult studies, commonly involves attenuated mood symptoms; and sleep disturbance may be a marker clinically (see reference for detailed discussion of prodrome). 
| Limitations, gaps, and future directions
Remaining controversies include whether ADHD might be a prodrome for BD. Some studies suggest that ADHD might be a prodrome, 94, 95 although some used interviews that blurred the distinction between mood episodes and more chronic presentations. 44 Longitudinal studies of ADHD cohorts tend to find no or only small increases in risk of BD. 96 Adding the DMDD diagnosis to DSM-5 created several gaps in terms of evidence-based assessment methods to differentiate DMDD from mood disorders, and lack of clarity regarding effective treatments. DMDD has its own definitional problems, as irritability includes both mood (often loses temper) and behavior (what happens when temper is lost). 46 The next version of ICD will not add DMDD as a diagnosis, instead making a mood disturbance specifier for ODD.
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Research needs to evaluate the relative effectiveness of psychosocial (eg, parent training; emotion regulation strategies) and pharmacologic interventions for DMDD. 61, 98 Longitudinal data also raise interesting questions about the possibility of remission of DMDD and bipolar disorders, 55 ,99 a topic that warrants further study.
| MEASUREMENT
| Established findings and consensus
There has been a large increase in the number of scales available and supported by data to measure different aspects of PBD. Myths ready for retirement include: (i) there is no validated rating scale or checklist for assessing manic symptoms in youth, (ii) a profile of scores on the CBCL 51 can be used as a proxy for a diagnosis of PBD, and (iii) thinking in polarized terms about the value of a particular informant perspective in the evaluation of PBD (see Table 1 ). Common (and mistaken)
beliefs include "teacher report is essential for confirming a diagnosis of mania," vs "teacher report is useless in the evaluation of PBD", or "parents' perspective is always right" vs "parents' perspective is hopelessly contaminated by their own mood or agenda."
| Current state of assessment
The current generation of practitioners completed their training before the bulk of research on PBD was available. Consequently, agreement between clinicians about the presence or absence of PBD in a particular case is poor. 100, 101 Agreement also tends to be worse around CycD and OS-BRD, 23, 102 which is unfortunate given that these may be more common than BD-I.
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| Cross-informant report on checklists
Multiple studies have evaluated parent, youth, and teacher report on both broad symptom checklists, such as the Achenbach System of Empirically Based Assessment, 51 and manic symptom scales.
Agreement between informants on ratings of the youth's mood symptoms tends to be only "fair," ie, in the r = .2 to .3 range, consistent with meta-analyses of agreement about youth mood and behavior in general.
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Checklists can detect cases needing more in-depth evaluation for potential PBD. A recent meta-analysis found 63 effect sizes-38 based on caregiver, 14 on youth, and 11 on teacher report, with eight checklists providing at least two different effect sizes. Teacher and youth reports had medium effect sizes, and parent/caregiver reports had the largest effect sizes. The Achenbach Externalizing Scale outperformed the putative "bipolar" profile, consistent with findings that the "bipolar" profile is not specific to PBD. 104 clear algorithm for CycD or OS-BRD-a key omission given the data on prevalence and burden. Structured interviews could be redesigned to better capture duration, potential prodrome, and trajectories. Rapid changes in Internet-based and smartphone delivery of clinical assessments need to be integrated with traditional assessment and treatment. Finally, feasibility, acceptability and utility of translation of research tools into real-world measurement-based care need to be studied.
| Risk factors as part of clinical evaluation
| PHARMACOLOGIC TREATMENT
| Established findings and consensus
This section summarizes extant literature about pharmacologic treatment of PBD, emphasizing RCTs. For additional detail, the reader is referred to recent reviews on this topic. An early meta-analysis on the treatment of PBD (N = 2666 participants across 46 trials) reported that SGAs were highly efficacious and superior to the modest anti-manic effects for traditional moodstabilizing agents, such as lithium carbonate, divalproex sodium, and carbamazepine, when used as monotherapy. 129 Another meta-analysis of double-masked placebo-controlled RCTs of treatment for BD-I mania among youth (n = 1609) and adults (n = 6501) found that SGAs were more efficacious but more metabolically burdensome compared to traditional mood stabilizers among youth, but showed no such differences among adults. 132 However, these meta-analyses predated recent studies supporting the efficacy of lithium.
The anticonvulsants divalproex sodium and carbamazepine have not fared well head-to-head with SGAs. In two meta-analyses, treatment effect was less robust with anticonvulsants than with SGAs. 105, 106 An RCT of divalproex extended release was negative, 131 as was a large RCT of oxcarbazepine, 110 and a topiramate RCT in youth was interrupted prior to its completion due to negative results in adult studies;
it failed to show efficacy in youth given inadequate power. 133 A study of 10 outpatients with BD (11-17 years old) whose weight increased by > 5% during treatment with mood-stabilizer or antipsychotic monotherapy were switched to topiramate; reductions in manic symptoms and weight were observed. 133, 134 In the "Treatment of Early Age Mania" 8-week trial, which included 290 youths aged 6-15 years with BD-I manic or mixed episodes, response rates were 68% for risperidone, 35% for lithium, and 24% for divalproex sodium. 135 The advantage of risperidone vs lithium was greater for youth with ADHD (vs non-ADHD) and non-obese (vs obese)
youth. 136 However, rates of comorbid ADHD in this study were > 90%, limiting power for ADHD vs no-ADHD comparisons, and some sites showed similar response rates for risperidone and lithium. Concerns have been raised regarding several characteristics in this sample, including prolonged episodes, very early childhood onset, and high rates of rapid cycling, constraining comparisons with adult studies. 
| Bipolar depression
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Although children randomized to aripiprazole, vs placebo, were enrolled significantly longer until time to discontinuation for a mood event or for any reason, the study was constrained by high drop-out rates within the first 4 weeks (50% for the aripiprazole group; 90%
for the placebo group), understood by the authors as a nocebo effect.
No significant between-group treatment effects on symptom rating or changes over time were observed for mania, depression, general impression, or global assessment. Another placebo-controlled continuation study of aripiprazole (10 mg or 30 mg) in youths (10-17 years old) with manic/mixed episodes followed participants for 26 weeks under double-blind conditions after a 4-week acute treatment phase. 
| Comorbidity
Positive results have been reported regarding the treatment of comorbid ADHD with mixed amphetamine salts and methylphenidate, albeit in modest-sized samples, particularly in euthymic youth.
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Aripiprazole did not differ from placebo in ADHD symptom reduction. 157 Preliminary findings from open trials and case reports suggest promise for adjunctive atomoxetine. 158 Although stimulants, as well as antidepressants, hold some risk of precipitating mania, precise estimates of this risk are lacking, both with and without ongoing mood stabilizer cotreatment. 145 A single small RCT found that lithium improved mood symptoms and comorbid substance use disorder among adolescents with, or at risk for, BD. 
| Nutritional interventions
| PSYCHOSOCIAL TREATMENTS
| Established findings and consensus
| NEUROIMAGING AND NEUROCOGNITION
| Established findings and consensus
Prevailing pathophysiologic models of BD implicate abnormalities in brain regions that regulate emotion and attention, namely the emotional control network (ECN). 187 The ECN is comprised of ventrolateral and ventromedial prefrontal networks, which modulate the limbic system, specifically the amygdala, in conjunction with subcortical nuclei, such as the thalamus and striatum. 187, 188 Increasing evidence suggests that there are anatomical, neurochemical, functional and cognitive abnormalities within the ECN in PBD. 188, 189 Pathophysiologic abnormalities underlying other cognitive functions that are altered in BD, such as reward processing, have also been studied. 
| Neuroimaging
Brain structure
Within the ECN, the amygdala plays a central role in emotional regulation. Two meta-analyses of magnetic resonance imaging (MRI) studies reported that youth with PBD present with smaller amygdala volumes compared with controls. 191, 192 One prospective study that evaluated youth after their first manic episode showed that amygdala volumes failed to show a normal increase with aging in patients, whereas this did not occur in controls or in youth with ADHD, suggesting that hampered neurodevelopment of the amygdala may underlie the dysfunctional emotional processing present in the ventral-limbic pathway. fronto-temporal, amygdala-hippocampus and amygdala-precuneus functional connectivity alterations, [210] [211] [212] with similar alterations observed during bipolar depression. 213 Together, these studies suggest that PBD is characterized by abnormal prefrontal-limbic functional connectivity in the processing of emotion, attention, and reward. Although still too preliminary to allow any definitive conclusions about the neurophysiology of PBD, these findings converge with adult BD findings.
Brain chemistry
Proton magnetic resonance spectroscopy studies are particularly important to help understand two current neurobiological hypotheses of BD, ie, glutamatergic dysfunction and mitochondrial dysfunction or energy metabolism dysfunction. Several studies in PBD have shown abnormalities in glutamate or glutamine levels in prefrontal brain areas. 214, 215 Abnormal levels of metabolites that are considered to be biomarkers of mitochondrial dysfunction or cell energy metabolism, such as decreased N-acetyl-aspartate or increased myo-inositol levels, were found in dorsal and ventral areas of the prefrontal cortex in PBD. [216] [217] [218] [219] [220] [221] [222] [223] [224] Although very valuable given the possibility of in vivo measurement of metabolites that might relate to pathophysiologic processes of neuronal integrity/viability, glutamatergic neurotransmission, and cell energy metabolism, the exact meaning of these results is poorly understood, partly because they are difficult to replicate or to predict. For instance, although several proton spectroscopy studies reported positive results for specific metabolite differences between patients and controls (eg, N-acetyl-aspartate or glutamine), 215, 220, 223, 224 within the same experiment, results are often negative for other metabolites (eg, creatine, myo-inositol and choline). 
| Neuroimaging in relation to treatment
There is a preliminary literature regarding neuroimaging studies in relation to treatment of PBD. For instance, an association between change in prefrontal glutamate concentrations and change in manic symptoms was reported in patients who achieved remission of mania after treatment with divalproex sodium. 225 Remission of mania after olanzapine treatment was associated with an increase in ventromedial prefrontal N-acetyl aspartate and choline levels. 
| Neurocognition
PBD is associated with impairment in several cognitive domains.
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A meta-analysis of 10 cognitive studies reported overall cognitive deficits in PBD (n = 352) compared to healthy controls (HCs; In a study of 30 adolescents with PBD, hypomanic symptoms were associated with levels of high-sensitivity c reactive protein (hsCRP).
Brain-derived neurotrophic factor (BDNF) and interleukin 6 (IL-6) were negatively associated with each other, and cardiovascular high-risk levels of hsCRP were observed in 40% of the sample. 
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A recent study of 30 adolescents with BD found that oxidative stress markers were lower as compared to adults with BD, and lipid hydroperoxide (LPH) levels were associated with a proxy measure of atherosclerosis but not with mood symptoms or medications.
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A population-based study of young adults found that those with Whereas the CACNA1C rs1006737 SNP has been previously associated with adult BD in genome-wide association studies, 255 it was the rs10848632 CACNA1C SNP that was nominally associated with PBD in SNP analyses. terms of parsing PBD from chronic irritability without episodic mania/ hypomania, in terms of increased recognition of PBD, and in terms of screening and diagnostic instruments, the field is now better positioned to examine this topic than it was as recently as a decade ago.
In terms of pathophysiology, it is important to consider the context of the Research Domain Criteria (RDoC) initiative, which suggests the value of integrating dimensional liability traits alongside DSMdriven diagnoses and diagnostic criteria. In addition to all the inherent complexity of BD in adults, including differences across mood states, comorbidities, and BD subtypes, among others, research focusing on youth includes the added challenge of developmental differences.
Future research should focus on age effects on the biology, manifestations, and treatment of PBD.
Future research should also focus on meaningfully integrating multiple methodologic levels of analysis. Thus far, there is a paucity of research that combines, for example, multiple neuroimaging approaches, neuroimaging and/or neurocognition with biomarkers, and/ or neurobiology and clinical epidemiology. To the extent that the field can apply the large sample sizes and prospective measures of cohort studies toward improved understanding of the neurobiology of PBD, findings will become increasingly clinically and heuristically relevant.
From a treatment perspective, it will be important to begin addressing functional outcomes, rather than simply focusing on symptom reduction. Even during recovery, youth with PBD demonstrate impaired psychosocial functioning. Improved understanding of the factors underlying these impairments will allow for targeted preventive and treatment approaches. More studies with longer periods of acute treatment and maintenance studies will both help to clarify stabilization and relapse prevention. Representative epidemiologic, not just clinical, PBD samples show very high rates of suicidality and multicomorbidity alongside very low rates of treatment, even though "overtreatment" and "over-diagnosis" garner more attention. 258, 259 The high degree of complexity and severity of PBD, even in the relatively early years of the disease, is in part an outcome of delaying or avoiding treatment altogether. It is crucial that the clinical and scientific community continues collaborative efforts, together with consumers, families, schools, and other stakeholders, toward public education and stigma reduction.
Finally, prevention strategies must be an area of emphasis in the decade ahead. Findings suggest that some psychotherapies and perhaps nutritional interventions might be low-risk options for early stage/prodromal intervention. Here, prevention refers not only to the prevention of BD, which is an important but relatively distal goal, but also to the prevention of comorbidity accumulation (eg, substance use disorders), suicidality, treatment refractoriness, neurocognitive and functional impairment, and adverse physical health outcomes. Indeed, the physical implications of BD, particularly in terms of future cardiovascular disease, are increasingly recognized. 79 Just as it is important for primary care providers to recognize the increased cardiovascular risk associated with PBD, it is important for our own field to begin integrating brain−body considerations in the assessment and treatment of PBD. The therapeutic and preventive potential of physical exercise for PBD, for example, is an almost entirely untouched topic. 260, 261 While many questions remain unanswered, or insufficiently answered, we are hopeful that progress over the next decade will be far less constrained by controversies that, although critical in defining the directions of the field, also slowed progress and limited collaboration. Dr. Chang is an unpaid consultant for GSK, Lilly, and BMS. He is on the DSMB for Sunovion. In the past 3 years he has received research support from GSK and Merck, and has been a consultant
